Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.62 |
| ▸ | NQO2 | P16083 | 13/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5430370 | 0.99 | MTNR1A (0.61) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL6566484 | 0.88 | MTNR1A (0.55) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL5181042 | 0.84 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL6567004 | 0.84 | MTNR1A (0.68) | MTNR1AMTNR1BNQO2HTR2C | |
| Hydrochloric Acid SCHEMBL5425189 | 0.83 | MTNR1A (0.67) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL5180707 | 0.80 | MTNR1A (0.65) | MTNR1AMTNR1BNQO2HTR2C | |
| Hydrochloric Acid SCHEMBL5430693 | 0.79 | MTNR1A (0.64) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL6245857 | 0.77 | MTNR1A (0.77) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL7950293 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HTR2C | |
| SCHEMBL4685402 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466604-B1 | Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems | SERVIER LAB (FR) | 2007-11-07 | — | — | EP | claimed |
| US-20070191328-A1 | Isoquinoline compounds | LES LABORATOIRES SERVIER (FR) | 2007-08-16 | — | — | US | claimed |
| US-7214689-B2 | Isoquinoline compounds | LES LABORATOIRES SERVIER (FR) | 2007-05-08 | — | — | US | claimed |
| US-20040204449-A1 | New isoquinoline compounds | LES LABORATOIRES SERVIER (FR) | 2004-10-14 | — | — | US | claimed |
| EP-1466604-A1 | Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems | Les Laboratoires Servier (FR) | 2004-10-13 | — | — | EP | claimed |
| CN-1535957-A | New isoquinoline compounds, their preparation method and medicine composition contaning them | ɪά��ʵ���� | 2004-10-13 | — | — | CN | claimed |
| EP-1466604-B1 | Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems | SERVIER LAB (FR) | 2007-11-07 | — | — | EP | disclosed |
| US-20070191328-A1 | Isoquinoline compounds | LES LABORATOIRES SERVIER (FR) | 2007-08-16 | — | — | US | disclosed |
| US-7214689-B2 | Isoquinoline compounds | LES LABORATOIRES SERVIER (FR) | 2007-05-08 | — | — | US | disclosed |
| JP-2004307492-A | NEW ISOQUINOLINE COMPOUND, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LAB SERVIER | 2004-11-04 | — | — | JP | disclosed |
| US-20040204449-A1 | New isoquinoline compounds | LES LABORATOIRES SERVIER (FR) | 2004-10-14 | — | — | US | disclosed |
| EP-1466604-A1 | Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems | Les Laboratoires Servier (FR) | 2004-10-13 | — | — | EP | disclosed |
| CN-1535957-A | New isoquinoline compounds, their preparation method and medicine composition contaning them | ɪά��ʵ���� | 2004-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204449-A1 | New isoquinoline compounds | MTNR1A, MTNR1B, HCRTR1 | MTNR1A 1/4885MTNR1B 2/4885NQO2 272/4885 |
| US-20070191328-A1 | Isoquinoline compounds | MTNR1A, MTNR1B, NR1D1 | MTNR1A 1/4885MTNR1B 2/4885NQO2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.